Literature DB >> 14594514

Dendritic cell culture: a simple closed culture system using ficoll, monocytes, and a table-top centrifuge.

Christina M Celluzzi1, Craig Welbon.   

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells involved in the induction of T cell-mediated immune responses and as such have emerged as important candidates for cellular-based therapies. Critical to safe clinical use is the easy manipulation of DCs and their precursors in a closed system. We have developed a serum-free, closed culture system applying a simple wash-Ficoll centrifugation method to reduce platelet and red blood cell (RBC) contamination. This procedure optimized adherence of monocytes (44 +/- 10.9% recovery, >85% expressed CD14(+)/CD163(+)) for the generation of DCs from mononuclear cell (MNC) apheresis units. Most RBCs and up to 98% of platelets were removed. Following density sedimentation, cell viability remained high (98 +/- 2%) with only minimal loss of monocytes (3 +/- 3%). Importantly, Ficoll-treated monocytes retained their ability to differentiate to mature DCs demonstrated by morphology, phenotype (MHC class II(+), CD1a(+), CD80(+), CD86(+), and CD83(+)), ability to stimulate mixed lymphocyte responses (MLR), present antigen, and produce interleukin-12 (IL-12). Nonadherent CD3(+) (80 +/- 4%) were also isolated for functional assays. Ficoll can be easily incorporated into a simple adherence-based closed system for collection of lymphocytes and adherent monocytes for DC culture. The procedure is relatively fast (effective working time 5-6 h), does not impair monocyte function or induce substantial cell activation, and can be performed economically using equipment found in a typical blood banking environment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594514     DOI: 10.1089/152581603322448286

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  1 in total

1.  A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.

Authors:  Silvija Jarnjak-Jankovic; Hege Hammerstad; Stein Saebøe-Larssen; Gunnar Kvalheim; Gustav Gaudernack
Journal:  BMC Cancer       Date:  2007-07-03       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.